ArticleHormones (Athens, Greece)2026
Sex-dependent PRRT toxicity in patients with metastatic somatostatin receptor-avid neuroendocrine tumors treated with
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess risk factors for peptide receptor radionuclide therapy (PRRT)-related toxicity to the kidneys, liver, and bone marrow (BM).
methodsThis is a retrospective study of patients with advanced, well-differentiated neuroendocrine neoplasms treated with
resultsIn 178 PRRT cycles in 47 patients (53.2% women, median age 65 years), eight patients had hematological toxicity grade ≥ 2 and seven had hepatic toxicity. A positive correlation was found between baseline and post-treatment BM, kidney, and liver markers. Similarly, a positive correlation was found between the post-treatment-to-pre-treatment marker ratio in the first cycle and the full-treatment-to-baseline ratio. Women had a more pronounced decrease in blood WBC count (last/1st measurement ratio, 0.52 ± 0.17 vs. 0.72 ± 0.19, p < 0.001, women vs. men, respectively), with a similar trend for hemoglobin (Hb) concentration (0.97 ± 0.08 vs. 1.01 ± 0.10, p = 0.090) during treatment. In the logistic regression, women's risk for neutrophil impairment was 8.7 times higher than men's (p = 0.034).
conclusionBaseline assessment reflects the patient's reserves and their post-PRRT state. Further, women are more prone to BM-related toxicity from PRRT. These insights can help optimize treatment strategies and improve patient outcomes in this population.
Indexed as
Identifiers
41258636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.